SMZ1 Stock Overview
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.31 |
| 52 Week High | HK$0.50 |
| 52 Week Low | HK$0.29 |
| Beta | 0.52 |
| 1 Month Change | -11.86% |
| 3 Month Change | -8.77% |
| 1 Year Change | -36.91% |
| 3 Year Change | -64.41% |
| 5 Year Change | -46.50% |
| Change since IPO | 3,060.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| SMZ1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.2% | 3.2% | 1.7% |
| 1Y | -36.9% | -28.2% | 2.3% |
Return vs Industry: SMZ1 underperformed the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: SMZ1 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| SMZ1 volatility | |
|---|---|
| SMZ1 Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SMZ1 has not had significant price volatility in the past 3 months.
Volatility Over Time: SMZ1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 25,806 | Eric S. Y. Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection.
Sino Biopharmaceutical Limited Fundamentals Summary
| SMZ1 fundamental statistics | |
|---|---|
| Market cap | €5.86b |
| Earnings (TTM) | €238.19m |
| Revenue (TTM) | €3.38b |
24.6x
P/E Ratio1.7x
P/S RatioIs SMZ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMZ1 income statement (TTM) | |
|---|---|
| Revenue | CN¥26.20b |
| Cost of Revenue | CN¥4.99b |
| Gross Profit | CN¥21.21b |
| Other Expenses | CN¥19.36b |
| Earnings | CN¥1.85b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 80.95% |
| Net Profit Margin | 7.05% |
| Debt/Equity Ratio | 32.0% |
How did SMZ1 perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield46%
Payout RatioDoes SMZ1 pay a reliable dividends?
See SMZ1 dividend history and benchmarks| Sino Biopharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 11 2024 |
| Dividend Pay Date | Jul 05 2024 |
| Days until Ex dividend | 47 days |
| Days until Dividend pay date | 71 days |
Does SMZ1 pay a reliable dividends?
See SMZ1 dividend history and benchmarks